Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Clinical evidence

LunAIRo

98 evidence topics · 19 sources

Objective
Location and study date
Study design
Eligibility criteria
Key exclusion criteria and fatigue threshold in the design paper

“Current bothersome symptoms of insomnia (difficulty initiating or maintaining sleep, as distinct from unrefreshing sleep or other symptoms attributable to OSA). Participants treated with insomnia can be enrolled if symptoms are controlled” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Schizophrenia, schizoaffective disorder, generalized anxiety disorder or bipolar disorder according to DSM-5 criteria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Attempted suicide within 1 year prior to screening, or current suicidal ideation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Current bothersome symptoms of bladder outlet obstruction including difficulty initiating or maintaining urinary flow, straining, or sensation of incomplete bladder emptying” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Blood pressure >145/90 mmHg” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Narrow angle glaucoma” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Only participants who refuse or are intolerant to PAP and with a raw PROMIS-Fatigue score ≥17 (fatigue level above average of the population; a raw score of 17 is equivalent to a T-score of 50.4) are eligible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Treatment
Study outcomes
Rationale for using Apnea-Hypopnea index as the primary endpoint
Primary endpoint: proportion with at least 50% reduction in AHI4 at six months in the baseline abstract, May 2025, superseded in June 2025
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Participant flow in the ClinicalTrials.gov record
Milestone or reasonAD109Placebo
Started“329”“331”
Completed“250”“274”
Not completed“79”“57”
Adverse Event“12”“7”
Lost to Follow-up“24”“20”
Other/Not Reported“5”“2”
Physician Decision“2”“7”
Site Terminated by Sponsor“3”“2”
Withdrawal by Subject“33”“19”
Baseline characteristics
Baseline characteristics of the full analysis set in the ClinicalTrials.gov record
CharacteristicAD109 (n = 324)Placebo (n = 326)
Age, years, mean (SD)“57.2(10.26)”“57.4(10.72)”
Female“160”“138”
Male“164”“188”
Black or African American“58”“53”
White“238”“246”
Baseline AHI4 below 15“119”“125”
Baseline AHI4 15 to 30“109”“104”
Baseline AHI4 above 30“96”“97”
Baseline AHI4, events/hr, mean (SD)“24.03(16.692)”“24.69(18.735)”
Efficacy results
Week 26 change from baseline in AHI4, treatment policy and while-on-treatment estimands, in the ClinicalTrials.gov record
Estimand and armLS mean change, events/hrLower 95% CIUpper 95% CI
Treatment policy, AD109 (n = 324)“-3.88”“-5.37”“-2.39”
Treatment policy, placebo (n = 326)“0.21”“-1.24”“1.65”
While-on-treatment, AD109 (n = 240)“-5.83”“-7.51”“-4.15”
While-on-treatment, placebo (n = 293)“-0.02”“-1.55”“1.50”
Pooled phase 3 analysis: week 26 AHI adjusted for changes in REM sleep and BMI, on-treatment estimand
Model, LS mean (95% CI), events/h at week 26AD109 (n = 500)Placebo (n = 589)Estimated treatment difference (95% CI)p-value
Primary model for change from baseline in AHI“–6.1 (–7.3 to –4.9)”“0.1 (–1.0 to 1.2)”“–6.2 (–7.8 to –4.6)”“<0.0001”
Model adjusted for change in proportion of REM sleep“–5.7 (–7.1 to –4.2)”“0.2 (–1.1 to 1.4)”“–5.9 (–7.9 to –3.8)”“<0.0001”
Model adjusted for change in BMI“–5.1 (–6.4 to -3.8)”“–0.2 (–1.4 to 0.9)”“–4.9 (–6.6 to –3.1)”“<0.0001”
Health-related quality of life and patient-reported outcomes
Safety results
Non-serious adverse events in at least 5% of participants in either arm
Serious adverse events and deaths
EventAD109, affected / at risk (%)Placebo, affected / at risk (%)
All-cause mortality“0/328 (0.00%)”“0/327 (0.00%)”
Any serious adverse event“5/328 (1.52%)”“10/327 (3.06%)”
Acute myocardial infarction“0/328 (0.00%)”“1/327 (0.31%)”
Aortic dissection“1/328 (0.30%)”“0/327 (0.00%)”
Intracranial aneurysm“1/328 (0.30%)”“0/327 (0.00%)”
Ischaemic stroke“0/328 (0.00%)”“1/327 (0.31%)”
Suicide attempt“0/328 (0.00%)”“1/327 (0.31%)”
Pooled phase 3 analysis: heart rate and blood pressure, safety analysis set
MeasureAD109 (n = 653)Placebo (n = 646)p-value
Heart rate, beats/min, mean change (SD) to week 26, evening pre-PSG“2.0 (11.2)”“-0.7 (10.0)”Not reported
Heart rate, beats/min, mean change (SD) to week 26, morning post-PSG“3.4 (9.5)”“-0.7 (9.4)”Not reported
Heart rate ≥100 beats/min on study, n (%)“48 (7.4)”“28 (4.3)”“0.021”
Systolic blood pressure ≥140 mm Hg on study, n (%)“175 (26.8)”“168 (26.0)”“0.760”
Diastolic blood pressure ≥90 mm Hg on study, n (%)“146 (22.4)”“131 (20.3)”“0.368”
Study limitations
Summary
  • Publication status: results are available from a congress abstract, the registry results (first posted 2026-11-03), company releases, and the prospectus; the 2026 editorial on SynAIRgy described LunAIRo results as forthcoming.
  • Design: placebo-controlled for 51 weeks, with the primary endpoint at week 26; week 51 efficacy was analyzed as a tertiary endpoint. No active comparator was used, dose reduction was not permitted, and all 64 sites were in the United States.
  • Population: adults intolerant of or refusing PAP with a PROMIS-Fatigue raw score of at least 17, and a BMI cap of 40 (men) or 42 (women) kg/m2. Exclusions included bothersome insomnia, clinically significant cardiac disease, blood pressure above 145/90 mmHg, specified psychiatric disorders, and narrow angle glaucoma.
  • Eligibility AHI differs by source: protocol version 4.0 states AHI4 of more than 5 and up to 45, the registry states AHI of more than 5, and the baseline abstract states no upper limit. The design paper states caps could be added during the trial.
  • Severity mix: in the pooled phase 3 population, 51% had AHI below 20 events/h and 74% below 30, per the prospectus.
  • Endpoint change: the 2025 baseline abstract named the proportion with at least 50% AHI4 reduction at six months as the primary endpoint. Protocol amendment 4.0 (June 2025) reordered the primary and key secondary endpoints “to align with recent regulatory approvals for the treatment of OSA related to obesity”, after the registry's actual primary completion date (2025-05-07).
  • Estimands and missing data: the treatment policy estimand assumed data missing not at random with control-based imputation. The on-treatment estimand excluded data after treatment discontinuation with last observation carried forward and included 240 participants on AD109 and 293 on placebo, against 324 and 326 in the full analysis set. The company states the on-treatment estimand gave the most clinically relevant estimate, and attributes the smaller week 51 response to higher discontinuation with AD109 and control-based imputation. The topline release reported the on-treatment relative reduction (46.8%).
  • Analysis-set exclusions: participants at site 1308 were excluded from the full analysis set after the site was terminated.
  • Discontinuation: treatment discontinuation due to adverse events was 23.7% with AD109 and 6.6% with placebo by month 6 and 28.6% and 10.0% by month 12; overall treatment discontinuation at month 12 was 46.5% and 25.1% (prospectus, main cohort). In the registry, 250 of 329 participants on AD109 and 274 of 331 on placebo completed the study.
  • Patient-reported outcomes: AD109 did not significantly reduce the PROMIS-Fatigue T-score under either estimand, and no treatment effect was observed on PROMIS Sleep Impairment.
  • Pooled analyses: Patel et al. (2026a) reports the pooled 39.0% versus 18.8% responder result without an estimand label, while the prospectus labels the pooled 39% as on treatment. The prospectus states the phase 3 trials were not designed or powered to assess cardiovascular outcomes.
  • Clinical meaningfulness: at the pre-NDA meeting the FDA gave feedback on the clinical meaningfulness of the primary endpoint results and the limitations of the PROs, and indicated additional analyses and justification may be needed.
  • Sponsor: the prospectus describes LunAIRo as a trial the company initiated.